Autons team writes that such discrepancies may stem from differences in disease context, smaller sample sizes, limited statistical power, and variations in drug type, cohorts, and analytical methods
Glycaemic management in diabetes: old and new approaches
The NHS pathway under NICE TA1026 currently restricts tirzepatide to a BMI of 40 or above with four of five qualifying conditions, with the threshold widening over the next 12 years
Packets are pre-portioned for daily use
Stopping treatment is a valid choice but it should be an informed one, made with a clear plan in place, not an impulsive decision made in response to a tough week." Aaliyah Mallard, PharmD For more on what sustainable long-term success looks like on GLP-1 treatment, read our guide on maintaining weight loss long-term, or learn about breaking through weight loss plateaus if you're considering stopping because results have stalled